Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The CRC DRAW study will assess the sensitivity and specificity of the blood-based, Next-Gen CRC Screening Test for the detection of CRC.
The CRC DRAW study is a prospective, multi-center, observational study to validate the Next-Gen CRC Screening test for the detection of CRC. The study will collect blood samples from average-risk participants scheduled for screening colonoscopies.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Next-Gen CRC Screening Test | Adults 45 years of age and older who are at average risk of developing colorectal cancer and eligible for a screening colonoscopy |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Next-Gen CRC Screening Test | Diagnostic Test | The Next-Gen CRC Screening Test is a blood-based screening test for detection of CRC. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Sensitivity for CRC of the Next-Gen CRC Screening Test | Clinical Performance | blood collection up to 90 days from colonoscopy |
| Specificity for CRC of the Next-Gen CRC Screening Test | Clinical Performance | blood collection up to 90 days from colonoscopy |
| Measure | Description | Time Frame |
|---|---|---|
| Sensitivity for advanced precancerous lesions of the Next-Gen CRC Screening Test | Clinical Performance | blood collection up to 90 days from colonoscopy |
| Specificity for no colorectal neoplastic findings of the Next-Gen CRC Screening Test |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Previous personal history of CRC or precancerous lesions
Positive result from non-invasive screening test within the associated recommended intervals:
2.1 Fecal occult blood test or fecal immunochemical test within the previous 12 months 2.2 Epi proColon test within the previous 12 months 2.3 FIT-DNA (Cologuard) test within the previous 36 months
Diagnosed with condition associated with higher risk for colorectal cancer, such as:
3.1 Inflammatory bowel disease (IBD) 3.2 Chronic ulcerative colitis (CUC) 3.3 Crohn's disease 3.4 Familial adenomatous polyposis (FAP) 3.5 Familial history for colorectal cancer 3.5.1 One or more first-degree relatives diagnosed with CRC or adenomatous polyps before 60 years of age 3.5.2 Two or more first degree relatives diagnosed at any age with CRC
Individuals with relevant familial (hereditary) cancer syndrome, such as:
4.1 Hereditary non-polyposis colorectal cancer syndrome (HNPCC or Lynch Syndrome) 4.2 Peutz-Jeghers Syndrome 4.3 MYH-Associated Polyposis (MAP) 4.4 Gardner's syndrome 4.5Turcot's (or Crail's) syndrome 4.6 Cowden's syndrome, 4.7Juvenile Polyposis 4.8 Cronkhite-Canada syndrome 4.9 Neurofibromatosis 4.10 Familial Hyperplastic Polyposis
Diagnosed with chronic gastritis or cirrhosis
Current diagnosis of any cancer, except non-melanoma skin cancer
Overt rectal bleeding or bleeding hemorrhoids within previous 30 days
A colonoscopy within the previous 9 years, with the exception of a failed colonoscopy due to poor bowel preparation
Pregnancy
Not provided
Not provided
Not provided
Adults 45 years of age and older who are at average risk of developing colorectal cancer and eligible for a screening colonoscopy
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Gastro SB | Chula Vista | California | 91910 | United States | ||
| SDG Clinical Research |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Blood specimens will be de-identified and used to validate the performance characteristics of the Next-Gen CRC Screening Test. Blood samples may also be used for future research and development, feasibility and validation.
Clinical Performance
| blood collection up to 90 days from colonoscopy |
| San Diego |
| California |
| 92103 |
| United States |
| Medical Associates Research Group | San Diego | California | 92123 | United States |
| ID | Term |
|---|---|
| D015179 | Colorectal Neoplasms |
| D003110 | Colonic Neoplasms |
| D012004 | Rectal Neoplasms |
| D003108 | Colonic Diseases |
| D003111 | Colonic Polyps |
| D011127 | Polyps |
| D000236 | Adenoma |
| D012002 | Rectal Diseases |
| D005770 | Gastrointestinal Neoplasms |
| D007414 | Intestinal Neoplasms |
| D003109 | Colonic Diseases, Functional |
| D007410 | Intestinal Diseases |
| ID | Term |
|---|---|
| D004067 | Digestive System Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D004066 | Digestive System Diseases |
| D005767 | Gastrointestinal Diseases |
| D007417 | Intestinal Polyps |
| D020763 | Pathological Conditions, Anatomical |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D009375 | Neoplasms, Glandular and Epithelial |
| D009370 | Neoplasms by Histologic Type |
Not provided
Not provided